Mrs. Bảy, 71, has lived in Little Saigon for over thirty years and suffers from chronic knee pain. Three months ago, her daughter ordered a vial of BPC-157 online from a social media advertisement, believing the injectable was safe because it was sold openly and endorsed by influencers. She did not consult her family doctor. Cases like Mrs. Bảy's are not uncommon: a survey released in May 2026 of nearly 2,500 American adults showed that half of peptide users believed their injected products had been approved by the FDA — when in fact most have never undergone any form of vetting.
Many people believe peptides purchased online are as safe as prescription drugs — but most have never undergone FDA vetting.
How the black market mechanism operates
Peptides such as BPC-157, TB-500, KPV, and MOTs-C currently occupy a legal gray zone: they are sold as 'research only' products but are injected directly into users' bodies. The current restrictions stem from the Biden administration era, when regulators worried about safety risks but did not completely ban buying and selling, allowing products to continue circulating through overseas compounding pharmacies and e-commerce platforms. In essence, many of these lack clear evidence of effectiveness for the uses marketed by sellers, yet are still packaged attractively like premium functional supplements.
Why Washington is considering relaxing restrictions right now
An FDA advisory committee is scheduled to meet for two days on July 23 and 24, 2026 to discuss adding seven types of peptides — including BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, and Epitalon — to the list of compounds permitted for compounding according to prescription. If approved, domestic compounding pharmacies would be able to legally manufacture and sell these peptides, rather than leaving the market in the hands of unregulated suppliers. U.S. Health Secretary Robert F. Kennedy Jr., who previously called the 2023 ban illegal, is one of the strongest voices in favor of reversing this policy — a position that has sparked controversy in the medical community, which has previously expressed concern about his approach to other scientific advisory boards.
Concrete risks, not abstract concerns
This is not a theoretical issue. An analysis released in January 2026 found that roughly three in ten research-grade peptide products failed basic quality checks — mislabeled, impure, or with incorrect dosages. Meanwhile, a spontaneous wave of peptide self-injection is spreading alongside the trend of peptide-based weight loss drugs: about one in eight American adults have used GLP-1 class medications, and shortages in recent years have driven many people to unverified 'counterfeit' products from compounding pharmacies. For elderly first-generation refugee Vietnamese — a group that often places absolute trust in things marketed as 'tonics' or 'anti-aging treatments' — language barriers and gaps in medical literacy multiply the risks exponentially. Healthcare workers within the community, particularly family clinics serving elderly Vietnamese, are on the front lines encountering the consequences of this trend, even though they are not the ones prescribing these medications.
What to watch next
The FDA advisory committee's decision in late July will determine whether peptides will be brought into the official compounding pharmacy system or continue to drift through unregulated channels. In the meantime, the black market exists because Biden-era restrictions have not been replaced with a clearer legal framework. For elderly Vietnamese considering products like those Mrs. Bảy used, the most practical advice remains: ask your doctor before injecting anything advertised online, and find out whether the product is on the FDA-recognized list rather than trusting packaging or endorsements from influencers.
Read the original reports at the source links below.